JACOB D. BITRAN, M.D., F.A.C.P.; THOMAS DEMEESTER, M.D., F.A.C.S.; RICHARD K. DESSER, M.D.; HARVEY M. GOLOMB, M.D.
To the editor: The reports of Weiss (1), Livingston and co-authors (2), and Johnson, Brereton, and Kent (3) clearly indicate an improved prognosis and survival for patients with small-cell carcinoma of the lung. Our group at the University of Chicago has treated patients with small-cell carcinoma using a previously described combined modality program of radiation therapy and cyclophosphamide, doxorubicin and methotrexate with rescue (4). The results of this treatment program in 19 patients with clinically and pathologically staged "limited disease" stage IIIMO (disease confined to the lungs and mediastinum) and state IIISCN+ (disease confined to the ipsilateral hemithorax and supraclavicular
JACOB D. BITRAN, THOMAS DEMEESTER, RICHARD K. DESSER, HARVEY M. GOLOMB. Small-Cell Carcinoma of the Lung. Ann Intern Med. 1978;89:139. doi: 10.7326/0003-4819-89-1-139_1
Download citation file:
Published: Ann Intern Med. 1978;89(1):139.
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use